ACAD Long Put Strategy
ACAD (ACADIA Pharmaceuticals Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain.
ACAD (ACADIA Pharmaceuticals Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $5.04B, a trailing P/E of 13.28, a beta of 0.85 versus the broader market, a 52-week range of 19.69-29.84, average daily share volume of 1.7M, a public-listing history dating back to 2004, approximately 797 full-time employees. These structural characteristics shape how ACAD stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.85 places ACAD roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a long put on ACAD?
A long put buys downside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes below the strike minus premium at expiration.
ACAD snapshot
As of August 14, 2026, spot at $28.43, ATM IV 43.40%, IV rank 40.00%, expected move 12.44%. The long put on ACAD below is built from the August 14, 2026 end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 35-day expiry.
Why this long put structure on ACAD specifically: ACAD IV at 43.40% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 12.44% (roughly $3.54 on the underlying). The 35-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ACAD expiries trade a higher absolute premium for lower per-day decay. Position sizing on ACAD should anchor to the underlying notional of $28.43 per share and to the trader's directional view on ACAD stock.
ACAD long put setup
The ACAD long put below is built from the August 14, 2026 end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ACAD at $28.43 on that close, the first option leg uses a $28.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ACAD chain at a 35-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ACAD shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Put | $28.00 | $1.30 |
ACAD long put risk and reward
- Net Premium / Debit
- -$130.00
- Max Profit (per contract)
- $2,669.00
- Max Loss (per contract)
- -$130.00
- Breakeven(s)
- $26.70
- Risk / Reward Ratio
- 20.531
Max profit equals the strike minus premium times 100 (reached at zero); max loss equals the premium times 100. Breakeven is strike minus premium.
ACAD long put payoff curve
Modeled P&L at expiration across a range of underlying prices for the long put on ACAD. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | +$2,669.00 |
| $6.29 | -77.9% | +$2,040.51 |
| $12.58 | -55.8% | +$1,412.02 |
| $18.86 | -33.6% | +$783.52 |
| $25.15 | -11.5% | +$155.03 |
| $31.43 | +10.6% | -$130.00 |
| $37.72 | +32.7% | -$130.00 |
| $44.00 | +54.8% | -$130.00 |
| $50.29 | +76.9% | -$130.00 |
| $56.57 | +99.0% | -$130.00 |
When traders use long put on ACAD
Long puts on ACAD hedge an existing long ACAD stock position or express a bearish view with defined risk; position sizing typically scales the put notional to the underlying ACAD exposure being hedged.
ACAD thesis for this long put
The market-implied 1-standard-deviation range for ACAD extends from approximately $24.89 on the downside to $31.97 on the upside. A ACAD long put expresses a directional view that the underlying closes below the strike minus premium at expiration, frequently sized to hedge an existing long ACAD position with one put per 100 shares held. Current ACAD IV rank near 40.00% is mid-range against its 1-year distribution, so the IV signal is neutral; the long put thesis on ACAD should anchor more to the directional view and the expected-move geometry. As a Healthcare name, ACAD options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ACAD-specific events.
ACAD long put positions are structurally bearish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ACAD positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ACAD alongside the broader basket even when ACAD-specific fundamentals are unchanged. Long-premium structures like a long put on ACAD are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current ACAD chain quotes before placing a trade.
Frequently asked questions
- What is a long put on ACAD?
- A long put on ACAD is the long put strategy applied to ACAD (stock). The strategy is structurally bearish: A long put buys downside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes below the strike minus premium at expiration. With ACAD stock at $28.43 on the August 14, 2026 close, the strikes shown on this page are snapped to the nearest listed ACAD chain strike and the premiums come straight from that session's bid/ask midpoint.
- How are ACAD long put max profit and max loss calculated?
- Max profit equals the strike minus premium times 100 (reached at zero); max loss equals the premium times 100. Breakeven is strike minus premium. For the ACAD long put priced from the August 14, 2026 end-of-day chain at a 30-day expiry (ATM IV 43.40%), the computed maximum profit is $2,669.00 per contract and the computed maximum loss is -$130.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a ACAD long put?
- The breakeven for the ACAD long put priced on this page is roughly $26.70 at expiration, derived from the August 14, 2026 end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The ACAD market-implied 1-standard-deviation expected move in the same options snapshot is approximately 12.44%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long put on ACAD?
- Long puts on ACAD hedge an existing long ACAD stock position or express a bearish view with defined risk; position sizing typically scales the put notional to the underlying ACAD exposure being hedged.
- How does current ACAD implied volatility affect this long put?
- ACAD ATM IV is at 43.40% with IV rank near 40.00%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.